Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Urinary Bladder Neoplasms 2Lung Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Recurrent Lung Squamous Cell Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neoplasm Metastasis 1Meningeal Neoplasms 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Doxorubicin 3pazopanib 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Ifosfamide 2sapanisertib 1romidepsin 1pegfilgrastim 1metarrestin 1cixutumumab 1Temozolomide 1Specimen Handling 1Sorafenib 1Radiation 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1MLN 8237 1Ipilimumab 1HhAntag691 1Filgrastim 1Etoposide 1Diathermy 1CTLA-4 Antigen 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neurofibrosarcoma × sapanisertib × Clear all
NCT02601209 2022-08-23

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
151 enrolled 22 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡